The pharmaceutical industry is increasingly focused on improving therapeutic innovation while controlling research costs, shortening development timelines, and addressing unmet medical needs. Advances in artificial intelligence, bioinformatics, genomics, real-world data, and translational research are enabling researchers to identify new therapeutic applications for established medicines. These developments are strengthening the role of repurposing strategies across oncology, neurological disorders, rare diseases, and other complex therapeutic areas.

Drug Repurposing Market Size and Growth Outlook

The drug repurposing market size was valued at US$ 31.35 Billion in 2025 and is projected to reach US$ 43.06 Billion by 2034, expanding at a CAGR of 3.59% during 2026–2034. The expansion reflects increasing pharmaceutical interest in cost-efficient approaches for identifying new indications for existing drugs. Established safety information, manufacturing capabilities, and clinical data can reduce development risks compared with conventional drug discovery, supporting continued investment in repurposing programs.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00016853

Artificial Intelligence Transforming Drug Repurposing

Artificial intelligence and machine learning are emerging as important technologies shaping drug discovery and repurposing strategies. Advanced computational platforms can evaluate molecular interactions, genomic information, electronic health records, published research, and clinical datasets to identify potential relationships between existing medicines and new disease indications. The growing integration of predictive analytics and computational biology is helping pharmaceutical companies prioritize promising candidates and improve research productivity.

Growing Focus on Cost-Efficient Drug Development

The increasing pressure to control pharmaceutical R&D expenditure is a major factor supporting adoption of repurposing approaches. Existing medicines may have established safety profiles, manufacturing processes, pharmacological information, and clinical evidence, allowing researchers to focus resources on evaluating new therapeutic applications. This approach can provide pharmaceutical companies with opportunities to extend product lifecycles while addressing diseases where conventional drug development remains costly and time-consuming.

Oncology Remains a Major Growth Area

Oncology represents the largest disease-indication segment, supported by increasing cancer prevalence and continuous efforts to develop targeted and personalized treatment options. Pharmaceutical companies are evaluating approved compounds for additional cancer indications, particularly as biomarker research and precision medicine capabilities improve. The oncology segment is expected to register a CAGR of 3.8–4.2% during 2026–2034, highlighting its importance to overall industry expansion.

Real-World Data Supporting Market Development

The growing availability of electronic medical records, patient registries, healthcare databases, and other real-world data sources is creating new opportunities for identifying potential drug repurposing candidates. Researchers can analyze treatment outcomes and patient characteristics to detect previously unrecognized therapeutic effects. The increasing integration of real-world evidence with clinical research is expected to strengthen candidate validation and support more informed decisions throughout the drug development lifecycle.

Regional Growth Trends

North America is expected to remain the leading regional market, supported by sophisticated pharmaceutical research infrastructure, high clinical trial activity, advanced biotechnology capabilities, and increasing use of artificial intelligence in drug discovery. The region accounted for 39–43% of global revenue in 2025 and is projected to grow at a CAGR of 3.4–3.8% during 2026–2034. The US represents 84–88% of the North American market.

Asia Pacific is projected to be the fastest-growing regional market, with a CAGR of 4.3–4.7% through 2034. Expanding pharmaceutical manufacturing, biotechnology investments, clinical research capabilities, and computational drug discovery initiatives are supporting regional development. China, Japan, India, and South Korea are strengthening their pharmaceutical research ecosystems, while increasing investment in healthcare innovation is creating additional opportunities for repurposed therapies.

Competitive Landscape and Top Players

• Astellas Pharma Inc.

• Biovista, Inc.

• Novartis AG

• AbbVie Inc.

• Pfizer Inc.

• NuMedii, Inc.

• Abbott Laboratories

• F. Hoffmann-La Roche Ltd

• Johnson & Johnson

• Bristol-Myers Squibb Company

Future Trends and Growth Analysis

Future development is expected to be shaped by greater integration of AI-enabled candidate screening, real-world evidence, precision medicine, biomarker discovery, and collaborative research models. Pharmaceutical companies are increasingly combining computational analysis with translational research to improve candidate selection and reduce development uncertainty. Growing collaboration among pharmaceutical companies, biotechnology firms, universities, contract research organizations, healthcare providers, and technology companies is also expected to accelerate clinical validation and commercialization.

About US

The Insight Partners provides comprehensive syndicated and tailored market research services in the healthcare, technology, and industrial domains. Renowned for delivering strategic intelligence and practical insights, the firm empowers businesses to remain competitive in ever-evolving global markets.

Contact Us

Contact Person: Ankit Mathur
E-mail:[email protected]
Phone: +1-646-491-9876

Also Available in : Korean German Japanese French Chinese Italian Spanish